Nutcracker Therapeutics to Reveal NTX-472 at ASCO 2024 and Sachs Oncology Forum

Nutcracker Therapeutics, Inc., a biotechnology firm specializing in innovative RNA therapies, has revealed its latest preclinical drug candidate, NTX-472. This announcement was made in anticipation of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place in Chicago from May 31 to June 4.

NTX-472 is an advanced mRNA-encoded medication that targets three specific markers—CD20, CD19, and CD47—simultaneously. The company is developing this candidate for the treatment of B cell lymphoma, a type of cancer that affects the lymphatic system. The innovative use of engineered mRNA in NTX-472 allows for a multi-targeted approach, enhancing the potential effectiveness of the treatment.

The presentation of NTX-472 at ASCO 2024 is scheduled for June 1, with a poster session titled "Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma." This session will take place in Hall A from 9:00 a.m. to 12:00 p.m. CDT, led by Adrienne Sallets. Interested attendees can access the abstract titles and more details about the conference on the ASCO website.

In conjunction with the ASCO annual meeting, Nutcracker Therapeutics will also participate in the 10th Sachs Oncology Innovation Forum (OIF) on May 31. Dr. Nicole Fay, the director of pharmacology and the product lead for NTX-250, Nutcracker's leading candidate, will represent the company in two key events at the forum. At 2:40 p.m. CDT, she will join a panel discussion on "New Methods of Therapeutic Delivery for Oncology" at the Waldorf Astoria Chicago Hotel. Additionally, Dr. Fay will deliver a corporate presentation in Room Faulkner at 11:50 a.m. CDT.

Nutcracker Therapeutics leverages a proprietary RNA platform that integrates advanced engineering and precise biosynthesis. This platform streamlines the design, delivery, and manufacturing processes for RNA medicines, offering significant advantages in speed, cost reduction, and scalability compared to traditional methods. The company's technology has enabled the initiation of several therapeutic programs, supported by clinical investigators from top institutions.

The company's participation in these prestigious events highlights its commitment to advancing RNA therapeutic technology. Through its innovative approach, Nutcracker Therapeutics aims to provide transformative treatments for various diseases, particularly focusing on oncology.

Nutcracker Therapeutics continues to explore and develop RNA-based therapies, aiming to bring forth new solutions that can significantly improve patient outcomes. The potential of their technology to revolutionize the field of RNA medicine underscores their role as a leader in biotechnological innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!